首页> 外文期刊>Journal of the American Chemical Society >A Catalytic Asymmetric Bioorganic Route to Enantioenriched Tetrahydro-and Dihydropyranones
【24h】

A Catalytic Asymmetric Bioorganic Route to Enantioenriched Tetrahydro-and Dihydropyranones

机译:对映体富集的四氢和二氢吡喃酮的催化不对称生物有机路线。

获取原文
获取原文并翻译 | 示例
           

摘要

A conceptually novel approach to hetero Diels-Alder adducts of carbonyl compounds is described using as the key steps an antibody-mediated kinetic resolution of hydroxyenones followed by a ring-closure process.Various beta-hydroxyenones proved to be very good substrates for antibodies 84G3-and 93F3-catalyzed retro-aldol reactions,allowing the preparation of highly enantiomerically enriched(up to 99% ee)precursors of pyranones.An attractive feature of this methodology is the possibility to convert these acyclic-enantioenriched beta-hydroxyenones into tetrahydropyranones by a conventional Michael-type addition procedure or into the corresponding dihydropyranones using an alternative palladium-catalyzed oxidative ring closure.For the palladium-mediated cyclization,a biphasic system has been implemented that allows the direct preparation of enantiopure dihydropyranones from the corresponding racemic aldol precursors using a sequential antibody-resolution/palladium-cyclization strategy,without isolation of the intermediate enantioenriched hydroxyenones.This bioorganic route is best applied to the preparation of hetero Diels-Alder adducts otherwise derived from less nucleophilic dienes and unactivated dienophiles.
机译:描述了一种概念上新颖的羰基化合物杂Diels-Alder加合物的使用方法,该方法使用了抗体介导的羟基烯酮的动力学拆分以及随后的闭环过程作为关键步骤,各种β-羟基烯酮被证明是抗体84G3-的非常好的底物和93F3催化的逆醛醇缩合反应,可以制备高对映体富集(高达ee高达99%ee)的吡喃酮。该方法的一个吸引人的特征是可以通过常规方法将这些无环对映体富集的β-羟基烯酮转化为四氢吡喃酮迈克尔型加成方法或使用其他钯催化的氧化性闭环反应制得的相应二氢吡喃酮。对于钯介导的环化反应,已实现了双相体系,该体系允许使用顺序的外消旋羟醛前体直接从对映体纯的对映体二氢吡喃酮制备抗体拆分/钯环化策略这种生物有机途径最适合用于制备杂狄尔斯-阿尔德加合物,否则它们来自亲核性较低的二烯和未活化的亲二烯体。

著录项

  • 来源
    《Journal of the American Chemical Society》 |2005年第5期|p.1481-1486|共6页
  • 作者单位

    Contribution from the Chemistry Research Laboratory,University of Oxford Mansfield Road,Oxford OX1 3TA(UK),and GlaxoSmithKline,Medicines Research Centre,Gunnels Wood Road,Stevenage SGI 2NY(UK);

    Contribution from the Chemistry Research Laboratory,University of Oxford Mansfield Road,Oxford OX1 3TA(UK),and GlaxoSmithKline,Medicines Research Centre,Gunnels Wood Road,Stevenage SGI 2NY(UK);

    Contribution from the Chemistry Research Laboratory,University of Oxford Mansfield Road,Oxford OX1 3TA(UK),and GlaxoSmithKline,Medicines Research Centre,Gunnels Wood Road,Stevenage SGI 2NY(UK);

    Contribution from the Chemistry Research Laboratory,University of Oxford Mansfield Road,Oxford OX1 3TA(UK),and GlaxoSmithKline,Medicines Research Centre,Gunnels Wood Road,Stevenage SGI 2NY(UK);

    Contribution from the Chemistry Research Laboratory,University of Oxford Mansfield Road,Oxford OX1 3TA(UK),and GlaxoSmithKline,Medicines Research Centre,Gunnels Wood Road,Stevenage SGI 2NY(UK);

    Contribution from the Chemistry Research Laboratory,University of Oxford Mansfield Road,Oxford OX1 3TA(UK),and GlaxoSmithKline,Medicines Research Centre,Gunnels Wood Road,Stevenage SGI 2NY(UK);

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号